A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction

British Journal of Haematology

Volumn 154, Issue 2, 2011, Pages 271-274

  Cencini, Emanuele ^a   Sozzi, Elisa ^a   Sicuranza, Anna ^a   Fabbri, Alberto ^a   Raspadori, Donatella ^a   Lauria, Francesco ^a   Forconi, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; PROTEIN P53;

ADULT; AGED; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS REACTIVATION; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INFECTION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SATISFACTION; PILOT STUDY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROTEIN DEFECT; PYREXIA IDIOPATHICA; SIDE EFFECT; TREATMENT RESPONSE; VIRUS REACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 79959851127     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08602.x     Document Type: Letter

References (9)

1. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine, 343, 1910-1916.
2. van Dongen, J.J., Langerak, A.W., Bruggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Delabesse, E., Davi, F., Schuuring, E., Garcia-Sanz, R., van Krieken, J.H., Droese, J., Gonzalez, D., Bastard, C., White, H.E., Spaargaren, M., Gonzalez, M., Parreira, A., Smith, J.L., Morgan, G.J., Kneba, M. & Macintyre, E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, 2257-2317.
3. Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M. & Engert, A. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology, 23, 7024-7031.
4. Forconi, F., Rinaldi, A., Kwee, I., Sozzi, E., Raspadori, D., Rancoita, P.M., Scandurra, M., Rossi, D., Deambrogi, C., Capello, D., Zucca, E., Marconi, D., Bomben, R., Gattei, V., Lauria, F., Gaidano, G. & Bertoni, F. (2008) Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. British Journal of Haematology, 143, 532-536.
5. Hallek, M., Cheson, B.D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
6. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. & Gaidano, G. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinical Cancer Research, 15, 995-1004.
7. Stilgenbauer, S. & Dohner, H. (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. The New England Journal of Medicine, 347, 452-453.
8. Zelenetz, A.D., Abramson, J.S., Advani, R.H., Andreadis, C.B., Byrd, J.C., Czuczman, M.S., Fayad, L., Forero, A., Glenn, M.J., Gockerman, J.P., Gordon, L.I., Harris, N.L., Hoppe, R.T., Horwitz, S.M., Kaminski, M.S., Kim, Y.H., Lacasce, A.S., Mughal, T.I., Nademanee, A., Porcu, P., Press, O., Prosnitz, L., Reddy, N., Smith, M.R., Sokol, L., Swinnen, L., Vose, J.M., Wierda, W.G., Yahalom, J. & Yunus, F. (2010) NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network, 8, 288-334.
9. Zenz, T., Benner, A., Dohner, H. & Stilgenbauer, S. (2008) Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle, 7, 3810-3814.